Jefferies Bullish on Cubist's (CBST) CXA-201; Raises PT to $44
Tweet
Share
E-mailGet Alerts CBST Hot Sheet
Price: $101.94 --0%
Rating Summary:
6 Buy, 13 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Rating Summary:
6 Buy, 13 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
Jefferies is increasing its price target on Cubist Pharmaceuticals (Nasdaq: CBST) from $36 to $44, while maintaining its Buy rating on the stock.
Jefferies comments that Cubist's CXA-201 "is potentially the most potent Gram-negative antibiotic in development, particularly for the most worrisome pseudomonas infections...CXA-201 is a combination of a new, rapidly-actericidal cephalosporin CXA-101 and marketed tazobactam. In vitro, CXA-101 showed ~99% pseudomonas susceptibility (vs. ~85% for 4th-generation cephalosporin, cefepime; ~84% for new carbapenem, doripenem) in addition to enhancing activity against beta-lactam-resistant Enterobacteriaceae strains."
Cubist's CXA-201 also has more pseudomona coverage, while Forst Labs (NYSE: FRX) CAZ-104 and CEF104 "have potency towards a relatively infrequent carbapenem-resistant strain of Klebsiella pneumoniae (KPC)."
The Phase III for CXA-201 is expected to commence before the end of the year. Phase II data is expected out in the third quarter.
Jefferies new price target consists of a fair value of about $38 per share for Cubicin and $6 per share for CXA-201, which is discounted at 11 percent annually. Jefferies estimates an acquisition price of $50 for Cubist.
For more analyst coverage on Cubist, click here. For a ratings summary, click here.
Cubist shares are trading 3 percent stronger in the early session.
Jefferies comments that Cubist's CXA-201 "is potentially the most potent Gram-negative antibiotic in development, particularly for the most worrisome pseudomonas infections...CXA-201 is a combination of a new, rapidly-actericidal cephalosporin CXA-101 and marketed tazobactam. In vitro, CXA-101 showed ~99% pseudomonas susceptibility (vs. ~85% for 4th-generation cephalosporin, cefepime; ~84% for new carbapenem, doripenem) in addition to enhancing activity against beta-lactam-resistant Enterobacteriaceae strains."
Cubist's CXA-201 also has more pseudomona coverage, while Forst Labs (NYSE: FRX) CAZ-104 and CEF104 "have potency towards a relatively infrequent carbapenem-resistant strain of Klebsiella pneumoniae (KPC)."
The Phase III for CXA-201 is expected to commence before the end of the year. Phase II data is expected out in the third quarter.
Jefferies new price target consists of a fair value of about $38 per share for Cubicin and $6 per share for CXA-201, which is discounted at 11 percent annually. Jefferies estimates an acquisition price of $50 for Cubist.
For more analyst coverage on Cubist, click here. For a ratings summary, click here.
Cubist shares are trading 3 percent stronger in the early session.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Cummins (CMI) PT Lowered to $675 at Jefferies
- Intchains Group Ltd (ICG) PT Lowered to $2 at Benchmark Following 1H Results
- Deere (DE) PT Lowered to $728 at UBS as Agricultural Machinery Cycle Gets Closer
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
Jefferies & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
